Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reaching for the cure as progeria research comes of age at the 12th international scientific workshop.

Nature aging·2026
Same author

Balancing Risk, Benefit, and Reality: Navigating Early Phase Studies in Pediatric Diffuse Midline Glioma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Predictors of mortality of pediatric cancer patients admitted to the intensive care unit in a low-middle-income country.

Frontiers in pediatrics·2026
Same author

Descriptive and molecular analysis of pineal parenchymal tumors with clinical correlation.

BMC cancer·2025
Same author

Pediatric Life Support: 2025 International Liaison Committee on Resuscitation Consensus on Science With Treatment Recommendations.

Circulation·2025
Same author

Pediatric Life Support: 2025 International Liaison Committee on Resuscitation Consensus on Science With Treatment Recommendations.

Pediatrics·2025

Related Experiment Video

Updated: Jul 11, 2026

Detection of Nuclear Blebbing and DNA Leakage in Mammalian Cells by Immunofluorescence
06:23

Detection of Nuclear Blebbing and DNA Leakage in Mammalian Cells by Immunofluorescence

Published on: January 17, 2025

New approaches to progeria.

Mark W Kieran1, Leslie Gordon, Monica Kleinman

  • 1Dana-Farber Cancer Institute, Department of Pediatric Oncology, 44 Binney St, Boston, MA 02115, USA. mark_kieran@dfci.harvard.edu

Pediatrics
|October 3, 2007
PubMed
Summary
This summary is machine-generated.

Hutchinson-Gilford progeria syndrome (HGPS) is a rare genetic disorder offering insights into aging. Research identifies the LMNA gene mutation and explores farnesylation pathway drug targets for a new clinical trial.

More Related Videos

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders
10:28

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

Published on: April 3, 2021

The Replica Set Method: A High-throughput Approach to Quantitatively Measure Caenorhabditis elegans Lifespan
11:58

The Replica Set Method: A High-throughput Approach to Quantitatively Measure Caenorhabditis elegans Lifespan

Published on: June 29, 2018

Related Experiment Videos

Last Updated: Jul 11, 2026

Detection of Nuclear Blebbing and DNA Leakage in Mammalian Cells by Immunofluorescence
06:23

Detection of Nuclear Blebbing and DNA Leakage in Mammalian Cells by Immunofluorescence

Published on: January 17, 2025

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders
10:28

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

Published on: April 3, 2021

The Replica Set Method: A High-throughput Approach to Quantitatively Measure Caenorhabditis elegans Lifespan
11:58

The Replica Set Method: A High-throughput Approach to Quantitatively Measure Caenorhabditis elegans Lifespan

Published on: June 29, 2018

Area of Science:

  • Genetics
  • Molecular Biology
  • Aging Research

Background:

  • Hutchinson-Gilford progeria syndrome (HGPS) is a rare genetic disorder characterized by symptoms of rapid premature aging.
  • The disease provides a unique model for studying the fundamental processes of aging.
  • Understanding HGPS is crucial for insights into age-related diseases.

Purpose of the Study:

  • To review the clinical features of Hutchinson-Gilford progeria syndrome.
  • To detail the genetic basis, specifically mutations in the lamin A (LMNA) gene.
  • To explore potential therapeutic targets and ongoing clinical trials.

Main Methods:

  • Literature review of clinical characteristics and genetic findings in HGPS.
  • Analysis of molecular mechanisms involving prelamin A processing and farnesylation.
  • Summary of preclinical and clinical trial data.

Main Results:

  • Identified the specific LMNA gene mutation responsible for HGPS.
  • Elucidated the role of altered farnesylation in disease pathogenesis.
  • Established baseline data supporting a clinical trial.

Conclusions:

  • The LMNA gene mutation and altered farnesylation pathway are key to HGPS.
  • Targeting the farnesylation pathway presents a promising therapeutic strategy.
  • Significant progress has been made, enabling clinical trials for HGPS patients.